Cequent Pharmaceuticals, Inc is developing new
clinically compatible RNAi-based therapies.
10 December 2009
FDA Grants Cequent IND – Clears Way for First-Ever Clinical Trial of Orally Delivered
RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology
Watch Cequent Animation - Click Here!
Home | Company | People | Research | Partners | Media | Contact
Legal Notice | Privacy Policy | Site Map
